TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis
NASDAQ:TMDX - Nasdaq - US89377M1099 - Common Stock - Currency: USD
Overall TMDX gets a fundamental rating of 5 out of 10. We evaluated TMDX against 191 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and the financial health of TMDX get a neutral evaluation. Nothing too spectacular is happening here. TMDX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year TMDX was profitable.
In the past year TMDX had a positive cash flow from operations.
TMDX had negative earnings in 4 of the past 5 years.
In the past 5 years TMDX reported 4 times negative operating cash flow.
1.2 Ratios
TMDX has a Return On Assets of 4.41%. This is amongst the best in the industry. TMDX outperforms 81.68% of its industry peers.
With an excellent Return On Equity value of 15.51%, TMDX belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
With a decent Return On Invested Capital value of 3.98%, TMDX is doing good in the industry, outperforming 74.87% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.41% | ||
| ROE | 15.51% | ||
| ROIC | 3.98% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 8.03%, TMDX belongs to the top of the industry, outperforming 81.68% of the companies in the same industry.
With a decent Operating Margin value of 8.49%, TMDX is doing good in the industry, outperforming 76.96% of the companies in the same industry.
With a Gross Margin value of 59.36%, TMDX perfoms like the industry average, outperforming 57.59% of the companies in the same industry.
TMDX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.49% | ||
| PM (TTM) | 8.03% | ||
| GM | 59.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TMDX is destroying value.
The number of shares outstanding for TMDX has been increased compared to 1 year ago.
TMDX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TMDX has been reduced compared to a year ago.
2.2 Solvency
TMDX has an Altman-Z score of 3.84. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.84, TMDX is doing good in the industry, outperforming 75.39% of the companies in the same industry.
A Debt/Equity ratio of 2.23 is on the high side and indicates that TMDX has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 2.23, TMDX is doing worse than 83.77% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.23 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.84 |
ROIC/WACC0.46
WACC8.58%
2.3 Liquidity
A Current Ratio of 8.30 indicates that TMDX has no problem at all paying its short term obligations.
TMDX's Current ratio of 8.30 is amongst the best of the industry. TMDX outperforms 88.48% of its industry peers.
A Quick Ratio of 7.52 indicates that TMDX has no problem at all paying its short term obligations.
TMDX's Quick ratio of 7.52 is amongst the best of the industry. TMDX outperforms 89.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.3 | ||
| Quick Ratio | 7.52 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 231.17% over the past year.
Looking at the last year, TMDX shows a very strong growth in Revenue. The Revenue has grown by 82.74%.
The Revenue has been growing by 79.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)231.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
Revenue 1Y (TTM)82.74%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%49.83%
3.2 Future
The Earnings Per Share is expected to grow by 49.75% on average over the next years. This is a very strong growth
Based on estimates for the next years, TMDX will show a very strong growth in Revenue. The Revenue will grow by 21.08% on average per year.
EPS Next Y47.95%
EPS Next 2Y50.7%
EPS Next 3Y44.08%
EPS Next 5Y49.75%
Revenue Next Year26.11%
Revenue Next 2Y23.29%
Revenue Next 3Y20.96%
Revenue Next 5Y21.08%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 92.57 indicates a quite expensive valuation of TMDX.
Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 64.92% of the companies in the same industry.
When comparing the Price/Earnings ratio of TMDX to the average of the S&P500 Index (28.79), we can say TMDX is valued expensively.
A Price/Forward Earnings ratio of 62.57 indicates a quite expensive valuation of TMDX.
Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than the industry average as 68.59% of the companies are valued more expensively.
TMDX is valuated expensively when we compare the Price/Forward Earnings ratio to 21.38, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 92.57 | ||
| Fwd PE | 62.57 |
4.2 Price Multiples
66.49% of the companies in the same industry are more expensive than TMDX, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 58.26 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates TMDX does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 44.08% in the coming years.
PEG (NY)1.93
PEG (5Y)N/A
EPS Next 2Y50.7%
EPS Next 3Y44.08%
5. Dividend
5.1 Amount
TMDX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
93.5
-0.68 (-0.72%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners115.59%
Inst Owner Change-51.23%
Ins Owners3.16%
Ins Owner Change18.89%
Market Cap3.16B
Analysts81.18
Price Target117.94 (26.14%)
Short Float %29.02%
Short Ratio7.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.72%
Min EPS beat(2)-59.86%
Max EPS beat(2)16.42%
EPS beat(4)3
Avg EPS beat(4)244.45%
Min EPS beat(4)-59.86%
Max EPS beat(4)957.84%
EPS beat(8)6
Avg EPS beat(8)130.01%
EPS beat(12)9
Avg EPS beat(12)91.53%
EPS beat(16)10
Avg EPS beat(16)64.35%
Revenue beat(2)1
Avg Revenue beat(2)0.42%
Min Revenue beat(2)-7.28%
Max Revenue beat(2)8.12%
Revenue beat(4)3
Avg Revenue beat(4)6.85%
Min Revenue beat(4)-7.28%
Max Revenue beat(4)13.34%
Revenue beat(8)7
Avg Revenue beat(8)13.08%
Revenue beat(12)11
Avg Revenue beat(12)20.74%
Revenue beat(16)13
Avg Revenue beat(16)16.32%
PT rev (1m)0.22%
PT rev (3m)3.58%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.78%
EPS NY rev (1m)0%
EPS NY rev (3m)0.96%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0.07%
Revenue NY rev (3m)2.93%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 92.57 | ||
| Fwd PE | 62.57 | ||
| P/S | 7.16 | ||
| P/FCF | N/A | ||
| P/OCF | 64.81 | ||
| P/B | 13.84 | ||
| P/tB | 14.72 | ||
| EV/EBITDA | 58.26 |
EPS(TTM)1.01
EY1.08%
EPS(NY)1.49
Fwd EY1.6%
FCF(TTM)-2.39
FCFYN/A
OCF(TTM)1.44
OCFY1.54%
SpS13.05
BVpS6.76
TBVpS6.35
PEG (NY)1.93
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.41% | ||
| ROE | 15.51% | ||
| ROCE | 5.04% | ||
| ROIC | 3.98% | ||
| ROICexc | 7.27% | ||
| ROICexgc | 7.52% | ||
| OM | 8.49% | ||
| PM (TTM) | 8.03% | ||
| GM | 59.36% | ||
| FCFM | N/A |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score6
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.23 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 8.9 | ||
| Cap/Depr | 656.67% | ||
| Cap/Sales | 29.38% | ||
| Interest Coverage | 3.32 | ||
| Cash Conversion | 85.24% | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.3 | ||
| Quick Ratio | 7.52 | ||
| Altman-Z | 3.84 |
F-Score6
WACC8.58%
ROIC/WACC0.46
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)231.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
EPS Next Y47.95%
EPS Next 2Y50.7%
EPS Next 3Y44.08%
EPS Next 5Y49.75%
Revenue 1Y (TTM)82.74%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%49.83%
Revenue Next Year26.11%
Revenue Next 2Y23.29%
Revenue Next 3Y20.96%
Revenue Next 5Y21.08%
EBIT growth 1Y240.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year184.98%
EBIT Next 3Y78.84%
EBIT Next 5Y66.36%
FCF growth 1Y50.91%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y474.6%
OCF growth 3YN/A
OCF growth 5YN/A